Overview of Technological Development,Complications,and Grossing Techniques in Percutaneous Coronary Intervention

Abstract

Historical development of percutaneous coronary intervention (PCI) from percutaneous coronary transluminal angioplasty (PCTA) is outlined, along with the progression in the development of coronary artery stents—from the earliest bare-metal stents to drug-eluting stents to the current leading edge of bioresorbable and polymer-free stents. The early, medium, and late complications of PCTA and PCI are explained briefly, and with respect to stent development. Finally, common techniques to remove section stented vessels are outlined.

Keywords

Forensic pathology Coronary artery Stent Complication Forensic Grossing

Get full access to this article

View all access options for this article.

References

Weiss

A.J.

Elixhauser

Andrews

R.M.

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006–. Characteristics of operating room procedures in U.S. hospitals, 2011; 2014 Feb [cited 2015 Apr 13]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb170-Operating-Room-Procedures-United-States-2011.jsp.

Weiss

A.J.

Elixhauser

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006–. Trends in operating room procedures in U.S. hospitals, 2001—2011; 2014 Mar [cited 2015 Apr 13]. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb171-Operating-Room-Procedure-Trends.pdf.

O'Neill

W.W.

O'Neill

B.P.

The first generation of angioplasty. Circ Cardiovasc Interv. 2009 Feb; 2(1): 1–3. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCINTERVENTIONS.109.849950. PMID: 20031685.

Kent

K.M.

Bentivoglio

L.G.

Block

P.C.

Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1982 Jun; 49(8): 2011–20. https://dx-doi-org.web.bisu.edu.cn/10.1016/0002-9149(82)90223–5. PMID: 6211084.

Detre

Holubkov

Kelsey

Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med. 1988 Feb 4; 318(5): 265–70. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJM198802043180501. PMID: 2961993.

Levin

D.C.

Ganz

Friedman

Percutaneous transluminal coronary angioplasty with an over-the-wire system. Radiology. 1985 May; 155(2): 323–6. https://dx-doi-org.web.bisu.edu.cn/10.1148/radiology155.2.3157203. PMID: 3157203.

Venkitachalam

Kip

K.E.

Selzer

Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985–1986 PTCA and 1997–2006 Dynamic Registries. Circ Cardiovasc Interv. 2009 Feb; 2(1): 6–13. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCINTERVENTIONS.108.825323. PMID 20031687

Butany

Carmichael

Leong

S.W.

Collins

M.J.

Coronary artery stents: identification and evaluation. J Clin Pathol. 2005 Aug; 58(8): 795–804. https://dx-doi-org.web.bisu.edu.cn/10.116/jcp.2004.024174. PMID: 16049279. PMCID: PMC1770873.

Balcon

Beyar

Chierchia

Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J. 1997 Oct; 18(10): 1536–47. https://dx-doi-org.web.bisu.edu.cn/10.1093/oxfordjournals.eurheartj.a015133. PMID: 9347264.

10.

König

Schiele

T.M.

Rieber

Stent design-related coronary artery remodeling and patterns of neointima formation following self-expanding and balloon-expandable stent implantation. Catheter Cardiovasc Interv. 2002 Aug; 56(4): 478–86. https://dx-doi-org.web.bisu.edu.cn/10.1002/ccd.10249. PMID 12124956.

11.

Barragan

Rieu

Garitey

Elastic recoil of coronary stents: a comparative analysis. Catheter Cardiovasc Interv. 2000 May; 50(1): 112–9. https://dx-doi-org.web.bisu.edu.cn/10.1002/(SICI)1522-726X (200005)50: 1<112: : AID-CCD25>3.0.CO;2-X. PMID: 10816295.

12.

Ormiston

J.A.

Dixon

S.R.

Webster

M.W.

Stent longitudinal flexibility: a comparison of 13 stent designs before and after balloon expansion. Catheter Cardiovasc Interv. 2000 May; 50(1): 120–4. https://dx-doi-org.web.bisu.edu.cn/10.1002/(SICI)1522–726X (200005)50: 1<120: : AID-CCD26>3.0.CO;2-T. PMID 10816296.

13.

Kastrati

Dirschinger

Boekstegers

Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000 Jul; 50(3): 290–7. https://dx-doi-org.web.bisu.edu.cn/10.1002/1522-726X(200007)50:3<290::AID-CCD5>3.0.CO;2-W. PMID 10878624

14.

Hoffman

Jansen

König

Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur Heart J. 2001 Nov; 22(21): 2007–14. https://dx-doi-org.web.bisu.edu.cn/10.1053/euhj.2001.2606. PMID 11603908.

15.

Hoffmann

Mintz

G.S.

Haager

P.K.

Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol. 2002 Jun 15; 89(12): 1360–4 https://dx-doi-org.web.bisu.edu.cn/10.1016/S0002-9149(02)02347-0. PMID 12062728.

16.

Fishman

D.L.

Leone

M.B.

Baim

D.S.

A randomized comparison of coronary stent placement and balloon angioplasty and the treatment of coronary artery disease. N Engl J Med. 1994 Aug 25; 331(8): 496–501. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJM199408253310802. PMID: 8041414

17.

Cutlip

D.E.

Chauhan

M.S.

Baim

D.S.

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002 Dec 18; 40(12): 2082–9. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0735-1097(02)02597–4 PMID 12505217

18.

Butany

Veinot

J.P.

Atherosclerosis: Practical implications for pathologists. Short course presented at: 97th Meeting of the United States and Canadian Academy of Pathology; 2008 Mar 1–7. Denver, CO.

19.

Ajani

A.E.

Kim

H.S.

Waksman

Clinical trials of vascular brachytherapy for in-stent restenosis: update. Cardiovasc Radiat Med. 2001 Apr-Jun; 2(2): 107–13. https://dx-doi-org.web.bisu.edu.cn/10.1016/S1522-1865(00)00081-0. PMID 11340015

20.

Hansrani

Overbeck

Smout

Stansby

Intravascular brachytherapy: a systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2002 Nov; 24(5): 377–82. https://dx-doi-org.web.bisu.edu.cn/10.1053/ejvs.2002.1742. PMID 12435336.

21.

Fajadet

Morice

M.C.

Bode

Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005 Mar 1; 111(8): 1040–4 https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.0000156334.24955.B2. PMID 15723977.

22.

Colombo

Hall

Nakamura

Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995 Mar 15; 91(6): 1676–88. https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.9L6.1676. PMID 7882474

23.

Serruys

P.W.

van Hout

Bonnier

Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998 Aug 29; 352(9129): 673–81. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0140-6736(97)11128-X. PMID 9728982.

24.

Natsuaki

Toyofuki

Sirolimus-eluting stent implantation for ostial right coronary artery lesions: five-year outcomes from the j-Cypher registry. Cardiovasc Interv Ther. 2014 Jul; 29(3): 200–8. https://dx-doi-org.web.bisu.edu.cn/10.1007/s12928-013-0236-2. PMID: 24390936.

25.

Grube

Silber

Hauptmann

K.E.

TAXUS I: six- and twelvemonth results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003 Jan 7; 107(1): 38–42. https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.0000047700.58683.Al. PMID: 12515740.

26.

Stone

G.W.

Ellis

S.G.

Cox

D.A.

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15; 350(3): 221–31. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa032441. PMID: 14724301.

27.

Stone

G.W.

Moses

J.W.

Ellis

S.G.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8; 356(10): 998–1008. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa067193. PMID 17296824

28.

Spaulding

Daemen

Boersma

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8; 356(10): 989–97. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa066633. PMID 17296825.

29.

Kastrati

Mehilli

Pache

Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8; 356(10): 1030–9. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa067484. PMID 17296823.

30.

Nordmann

A.J.

Briel

Bucher

H.C.

Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006 Dec; 27(23): 2784–814. https://dx-doi-org.web.bisu.edu.cn/10.1093/eurheartj/ehl282. PMID 17020889.

31.

Stone

G.W.

Ellis

S.G.

Colombo

Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 Jun 5; 115(22): 2842–7. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULANONAHA.106.687186. PMID 17515458.

32.

Kirtane

A.J.

Gupta

Iyengar

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009 Jun 30; 119(25): 3198–206. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULATIONAHA.108.826479. PMID: 19528338.

33.

Chitkara

Gershlick

Second- versus first-generation drug-eluting stents. Interv Cardiol. 2010; 5(1): 23–6. https://dx-doi-org.web.bisu.edu.cn/10.15420/icr.2010.5.1.23.

34.

Machado

Raposo

Dores

Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. Coron Artery Dis. 2014 May; 25(3): 208–14. https://dx-doi-org.web.bisu.edu.cn/10.1097/MCA.0000000000000078. PMID: 24419038.

35.

Biondi-Zoccai

G.G.

Lotrionte

Agostoni

A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006 Nov; 27(22): 2667–74. https://dx-doi-org.web.bisu.edu.cn/10.1093/eurheartj/ehl334. PMID: 17053008.

36.

Mukherjee

Moliterno

D.J.

Second-generation drug-eluting stents and the continuous need for rapidly available real-world data. JACC Cardiovasc Interv. 2009 Dec; 2(12): 1236–9. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.jcin.2009.10.010. PMID: 20129550.

37.

Sefanini

Byrne

R.A.

Serruys

P.W.

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012 May; 33(10): 1214–22. https://dx-doi-org.web.bisu.edu.cn/10.1093/eurheartj/ehs086. PMID: 22447805.

38.

Bangalor

Toklu

Amoroso

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013 Nov 8; 347: f6625. https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.f6625. PMID: 24212107. PMCID: PMC3898413.

39.

Navarese

E.P.

Tandjung

Claessen

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013 Nov 6; 347: f6530. https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.f6530. PMID: 24196498. PMCID: PMC3819044.

40.

Meier

Bioabsorbable drug-eluting stent: winner or sinner?

BMJ. 2013 Nov 27; 347: f7091. https://dx-doi-org.web.bisu.edu.cn/10.1136/bmj.n091. PMID: 24284343.

41.

Serruys

P.W.

Onuma

Ormiston

J.A.

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010 Nov 30; 122(22): 2301–12. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULANONAHA.110.970772 PMID: 21098436.

42.

Serruys

P.W.

Onuma

Dudek

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011 Oct 4; 58(15): 1578–88. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.jacc.2011.05.050. PMID: 21958884.

43.

Serruys

P.W.

Chevalier

Dudek

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015 Jan 3; 385(9962): 43–54. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0140-6736(14)61455-0. PMID: 25230593.

44.

Puricel

Arroyo

Corpataux

Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015 Mar 3; 65(8): 791–801. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.jacc.2014.12.017. PMID: 25720622.

45.

Haude

Erbel

Verheye

Comparison of intermediate term late lumen loss after coronary implantation of bare or paclitaxel eluting absorbable metal scaffolds: results from the PROGRESS-AMS and BIOSOLVE-1 trials. J Am Coll Cardiol. 2012; 59(13s1): E203–E203. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0735-1097(12)60204–6.

46.

Haude

Erbel

Erne

Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013 Mar 9; 381(9869): 836–44. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0140-6736(12)61765–6. PMID: 23332165.

47.

Ormiston

J.A.

Serruys

P.W.

Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009 Jun; 2(3): 255–60. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCINTERVENTIONS.109.859173. PMID: 20031723.

48.

Nishio

Takeda

Kosuga

Decade of histological follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in humans: are bioresorbable scaffolds the answer?

Circulation. 2014 Jan 28; 129(4): 534–5. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULATIONAHA.113.003769. PMID: 24470476.

49.

Liu

Zhang

Wang

Tailoring of the dopamine coated surface with VEGF loaded heparin/poly-1-lysine particles for anticoagulation and accelerate in situ endothelialization. J Biomed Mater Res A. 2015 Jun; 103(6): 2024–34. https://dx-doi-org.web.bisu.edu.cn/10.1002/jbm.a.35339. PMID: 25256819.

50.

Wang

Chen

A novel antithrombotic coronary stent: lysine-poly(HEMA)-modified cobalt-chromium stent with fibrinolytic activity. J Biomater Sci Polym Ed. 2013; 24(6): 684–95. https://dx-doi-org.web.bisu.edu.cn/10.1080/09205063.2012.706470. PMID: 23565909.

51.

Wang

G.X.

Deng

X.Y.

Tang

C.J.

The adhesive properties of endothelial cells on endovascular stent coated by substrates of poly-1-lysine and fibronectin. Artif Cells Blood Substit Immobil Biotechnol. 2006; 34(1): 11–25. https://dx-doi-org.web.bisu.edu.cn/10.1080/10731190500428283. PMID: 16519401.

52.

Liu

Zeng

Liu

Surface modification with dopamine and heparin/poly-L-lysine nanoparticles provides a favorable release behavior for the healing of vascular stent lesions. ACS Appl Mater Interfaces. 2014 Jun 11; 6(11): 8729–43. https://dx-doi-org.web.bisu.edu.cn/10.1021/am5015309. PMID: 24731022

53.

Landau

Lange

R.A.

Hillis

L.D.

Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994 Apr 7; 330(14): 981–93. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJM199404073301407. PMID: 8121462.

54.

Waller

B.F.

“Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters”–the future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment. J Am Coll Cardiol. 1989 Apr; 13(5): 969–87. https://dx-doi-org.web.bisu.edu.cn/10.1016/0735-1097(89)90248–9. PMID: 2522472.

55.

Waller

B.E.

Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease. Hum Pathol. 1987 May; 18(5): 476–84. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0046-8177(87)80032–1. PMID: 2952575.

56.

Schwartz

R.S.

Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998 Apr 9; 81(7A): 14E-17E.https://dx-doi-org.web.bisu.edu.cn/10.1016/S0002-9149(98)00148–9. https://dx-doi-org.web.bisu.edu.cn/10.1016/S0002-9149(98)00191-X. PMID: 9551589.

57.

Schwartz

R.S.

The vessel wall reaction in restenosis. Semin Interv Cardiol. 1997 Jun; 2(2): 83–8. PMID: 9546996.

58.

Farb

Sangiorgi

Carter

A.J.

Pathology of acute and chronic coronary stenting in humans. Circulation. 1999 Jan 5–12; 99(1): 44–52. https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.99.1.44. PMID: 9884378.

59.

FDA Public Health Web Notification*: Information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER coronary stent. Silver Spring (MD): US Food and Drug Administration; 2003 Oct [cited 2015 Apr 13]. Available from: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm064528.htm.

60.

Suzuki

Kopia

Hayashi

Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001 Sep 4; 104(10): 1188–93. https://dx-doi-org.web.bisu.edu.cn/10.1161/hc3601.093987. PMID: 11535578.

61.

Klugherz

B.D.

Llanos

Lieuallen

Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002 May; 13(3): 183–8. https://dx-doi-org.web.bisu.edu.cn/10.1097/00019501-200205000-00008. PMID: 12131023.

62.

Virmani

Guagliumi

Farb

Localized hypersensitivity and late coronary thrombosis to a sirolimus-eluting stent: should we be cautious?

Circulation. 2004 Feb 17; 109(6): 701–5. https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.0000116202.41966.D4 PMID: 14744976.

63.

Otsuka

Yahagi

Ladich

Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. Circulation. 2015 Jan 20; 131(3): 322–4. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULATIONAHA.114.012658. PMID: 25601953.

64.

Nebeker

J.R.

Virmani

Bennett

C.L.

Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006 Jan 3; 47(1): 175–81. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.jacc.2005.07.071. PMID: 16386683.

65.

Nakazawa

Stent thrombosis of drug eluting stent: pathological perspective. J Cardiol. 2011 Sep; 58(2): 84–91. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.jcc.2011.07.004. PMID: 21839616.

66.

LUscher

T.F.

Steffel

Eberli

F.R.

Drug-eluting stent and coronary thrombosis : biological mechanisms and clinical implications. Circulation. 2007 Feb 27; 115(8): 1051–8. https://dx-doi-org.web.bisu.edu.cn/10.1161/CIRCULATIONAHA.106.675934. PMID: 17325255.

67.

Chen

Y.X.

Whitman

O'Brien

E.R.

Novel antiinflammatory vascular benefits of systemic and stent-based delivery of ethyliso propylamiloride. Circulation. 2004 Dec 14; 110(24): 3721–6. https://dx-doi-org.web.bisu.edu.cn/10.1161/01.CIR.0000146790.51331.BA. PMID: 15505102.

68.

O'Brien

E.R.

Antagonism of the alpha4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation. J Leukoc Biol. 2004 Jun; 75(6): 1016–21. https://dx-doi-org.web.bisu.edu.cn/10.1189/jlb.1203618. PMID: 15020653.

69.

Rippstein

Black

M.K.

Boivin

Comparison of processing and sectioning methodologies for arteries containing metallic stents. J Histochem Cytochem. 2006 Jun; 54(6): 673–81. https://dx-doi-org.web.bisu.edu.cn/10.1369/jhc.5A6824.2006. PMID: 16714423.

70.

Bradshaw

S.H.

Kennedy

Dexter

D.F.

Veinot

J.P.

A practical method to rapidly dissolve metallic stents. Cardiovasc Pathol. 2009 May-Jun; 18(3): 127–33. https://dx-doi-org.web.bisu.edu.cn/10.1016/j.carpath.2009.01.001. PMID: 19211268.